Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지

Differential Gene Expression after Adenovirus-Mediated p16 Gene Transfer in Human Non-Small Cell Lung Cancer Cells

폐암세포주에서 아데노바이러스 매개 p16 유전자 전달로 인한 유전자 발현의 변화

  • 박미선 (식품의약품안전청 국립독성연구원 유전독성과) ;
  • 김옥희 (식품의약품안전청 국립독성연구원 유전독성과) ;
  • 박현신 (식품의약품안전청 국립독성연구원 유전독성과) ;
  • 지승완 (식품의약품안전청 국립독성연구원 유전독성과) ;
  • 엄미옥 (식품의약품안전청 국립독성연구원 유전독성과) ;
  • 염태경 (식품의약품안전청 국립독성연구원 유전독성과) ;
  • 강호일 (식품의약품안전청 국립독성연구원 유전독성과)
  • Published : 2004.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

For the safety evaluation of adenovirus-mediated gene transfer, we investigated differential gene expressions after transfecting adenoviral vector containing p16 tumor suppressor gene (Ad5CMV-p16) into human non-small cell lung cancer cells. In the previous study, we showed adenovirus-mediated $p16^{INK4a}$ gene transfer resulted in significant inhibition of cancer cell growth. We investigated gene expression changes after transfecting Ad5CMV-p16, Ad5CMV (null type, a mock vector) into A549 cells by using cDNA chip and oligonucleotide microarray chip (1200 genes) which carries genes related with signal transduction pathways, cell cycle regulations, oncogenes and tumor suppressor genes. We found that $p16^{INK4a}$ gene transfer down regulated 5 genes (cdc2, cyclin D3, cyclin B, cyclin E, cdk2) among 26 genes involved in cell cycle regulations. Compared with serum-free medium treated cells, Ad5CMV-p16 changed 27 gene expressions, two fold or more on oligonucleotide chip. In addition, Ad5CMV-p16 did not seem to increase the tumorigenicity-related gene expression in A549 cells. Further studies will be needed to investigate the effect of Ad5CMV-p16 on normal human cells and tissues for safety evaluation.

Keywords

References

  1. Allan, D., Koven, A., Wild, A., Kamel-Reid, S. and Dube, I.D. (1996): Endogenous murine leukemia virus DNA sequences in murine cell lines: implications for gene therapy safety testing by PCR. Leukem Lymphom., 23, 375-381
  2. Anttila, S., Hirvonen, A., Vainio, H., Husgafvel-Pursiainen, K., Hayes, J.D. and Ketterer, B. (1993): Immunohistochemical localization of glutathione S-transferases in human lung cancer. Cancer Res., 53, 5643-5648
  3. Blaese, R.M. (1990): Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency with autologous Iympohocytes transduced with a human ADA gene. Hum. Gene Ther., 1, 327-362
  4. Blaese, R.M., Culver, K.W., Miller, A.D., Carter, C.S., Fleisher, T., Clerici, M., Shearer, G., Chang, L., Chiang, Y, Tolstoshev, P., et al. (1995): T Iympohocyte-directed gene therapy for ADA-SCID : initial trial results after 4 years. Science, 270, 475-480 https://doi.org/10.1126/science.270.5235.475
  5. Caroline, C., Min, K., Dka, O., Robert, W., Dai, K., Zhuangwu, L., Yung, H.C., Bali, M., Shiv, S., Prem, S. and Kenneth, C. (1998): Effects of adenovirus-mediated p161NK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene, 16, 265-272 https://doi.org/10.1038/sj.onc.1201493
  6. Costantini, L.C., Bakowska, J.C., Breakefield, X.O. and Isacson, O. (2000): Gene Therapy in the CNS. Gene Therapy, 7, 93-109
  7. European Society of Gene Therapy 10th Annual Meeting (2002): Adverse event the clinical trial of gene therapy for the X-linked severe combined immune deficiency disease (XSCID)
  8. Fisher, D.E. ed. (2001): Tumor Suppressor Genes in Human Cancer, Totowa, New Jersey, Humana press, pp.183-195
  9. Gene Therapy Clinical Trials (2004): J. Gene Med. website (www.wiley.co.uk/genetherapy/clinical/)
  10. Gilliland, ED., Harms, H.J., Crowell, R.E., Li, Y.F., Willink, R. and Belinsky, SA (2002): Glutathione S-transferase P1 and NADPH Quinone Oxidoreductase Polymorphisms are associated with aberrant promoter methylation of p161NK4a and $O^{6}$-methylguanine-DNA methyltransferase in sputum. Cancer Res., 62, 2248-2252
  11. Grimison, B., Langan, T.A. and Sclafani, R.A. (2000): $P16^{lnk4a}$ tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution. Cell Growth & Differentiation, 11, 507-515
  12. Habib, NA, Hodgson, H.J.F., Lemoine, N. and Pignatelli, M. (1999): A Phase I/II Study of Hepatic Artery Infusion with wtp53-CMV-AD in Metastatic Malignant Liver Tumours. Human Gene Therapy, 10, 2019-2034 https://doi.org/10.1089/10430349950017383
  13. Hall, M. and Peters, G. (1996): Genetic alterations of cyclins, cyclin-dependent kinases and Cdk inhibitors in human cancers. Adv. Cancer Res., 68, 67-108
  14. Harada, H., Nakagawa, K., Iwata, S. and Saito, M., Kumon, Y, Sakaki, S., Sato, K. and Hamada, K. (1999): Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res., 59, 3783-3789
  15. Jin, M., Inoue, S., Umemura, T, Moriya, J., Arakawa, M., Nagashima, K. and Kato, H. (2001): Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer, 34, 207-218
  16. Kamb, A. et al. (1994): A cell cycle regulator potentially involved in genesis of many tumour types. Science, 264, 436-440 https://doi.org/10.1126/science.8153634
  17. Kataoka, M., Wiehle, S., Spitz, F., Schumacher, G., Roth, JA and Cristiano, R.J. (2000): Down-regulation of bcl-2 is associated with p16lNK4-mediated apoptosis in non-small cell lung cancer cells. Oncogene, 19. 1589-1595
  18. Kawabe, S., Roth, J.A., Wilson, D.R. and Meyn, R.E. (2000): Adenovirus-mediated p161NK4a gene expression radiosensitizes non-small cell lung cancer cells in a p53dependent manner. Oncogene, 19, 47, 5359-5366
  19. Kim, M., Katayose, Y, Rojanala, L., Shah, S., Sgagias, M., Jang, L., Jung, YJ., Lee, S.H., Hwang, S.G. and Cowan, K.H. (2000): Induction of apoptosis in p161NK4A mutantcell lines by adenovirus-mediated overexpression of p161NK4A protein. Cell Death and Differentiation, 7, 706-711
  20. Kobayashi, S., Shirasawa, H., Sashiyama, H., Kawahira, H. and Kaneko, O.T. (1999): p161NK4a expression adenovirus vector to suppress cancer cell proliferation. Clin Cancer Res., 5, 12, 4182-4185
  21. Lee, J.H., Lee, C.T., Yoo, C.G., Hong, Y.K., Kim, C.M., Han, S.K., Shim, Y.S., Carbone, D.P. and Kim, Y.W. (1998): The inhibitory effect of adenovirus-mediated p161NK4a gene transfer on the proliferation of lung cancer cell line. Anticancer Res., 18, 5A, 3257-3261
  22. Lee, S.H., Kim, M.S., Kwon, H.C., Park, I.C., Park, M.J., Lee, C.T, Kim, Y.W., Kim, C.M. and Hong, S.I. (2000): Growth inhibitory effect on glioma cells of adenovirus-mediated p16/1NK4a gene transfer in vitro and in vivo. Int J. Mol. Med., 6, 559-563
  23. Mannervik, B. and Danielson, U.H. (1988): Glutathione transferases - structure and catalytic activity. CRC Crit. Rev. Biochem., 23, 283-337
  24. Melcher, A., Murphy, S. and Vile, R. (1999): Heat shock protein expression in target cells infected with low levels of replication-competent virus contributes to the immunogenicity of adenoviral vectors. Human Gene Therapy, 10, 1431-1442 https://doi.org/10.1089/10430349950017770
  25. Niklinski, J., Niklinska, W, Laudanski, J., Chyczewska, E. and Chyczewski, L. (2001): Prognostic molecular markers in non-small cell lung cancer. Lung Cancer, 34, S53-S58
  26. Park, K.H., Seol, J.Y, Kim, T.U., Yoo, C.G., Kim, Y.W, Han, S.K., Shim, Y.S. and Lee, C.T. (2001): An Adenovirus Expressing Mutant p27 Showed More Potent Antitumor Effects Than Adenovirus-p27 Wild Type. Cancer Res., 61, 6163-6169
  27. Pilaro, A.M. and Serabian, M.A. (1999): Safety Evaluation of Gene Therapies : Past, Present and Future. ASGT 2nd meeting
  28. Ranade, K. et al. (1995) : Mutations associated with familial melanoma impair p161NK4 function. Nature Genet., 10, 114-116
  29. Raymon, H.K., Thode, S. and Gage, F.H. (1997): Application of ex Vivo Gene Therapy in the Treatment of Parkinson's Disease. Experimental Neurology, 144, 82-91 https://doi.org/10.1006/exnr.1996.6392
  30. Roth, J.A., Swisher, S.G., Merritt, J.A., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., EI-Naggar, A.K., Fossella, F.V., Glisson, B.S., Hong, W.K., Khurl, F.R., Kurie, J.M., Nesbitt, J.C., Pisters, K., Putnam, J.B., Schrump, D.S., Shin, D.M., Walsh, G.L. (1998): Gene therapy for nonsmall cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol, 25(3 SuppI8), 33-37
  31. Seroogy, C.M. and Fathman, C.G. (2000): The application of gene therapy in autoimmune diseases. Gene Therapy, 7, 9-13
  32. Smith, K.T., Shepherd, A.J., Boyd, J.E. and Lees, G.M. (1996): Gene delivery systems for use in gene therapy: an overview of quality assurance and safety issues. Gene Therapy, 3, 190-200
  33. the European Agency for the Evaluation of Medicinal Products (2001): Note for guidance on the quality, preclinical and clinical aspects of gene transfer medicinal products
  34. U.S. NIH report (2002): Assessment of adenoviral vector safety and toxicity : report of the national institutes of health recombinant DNA advirosry committee. Human Gene Therapy, 13, 3-13
  35. US FDA Center for Biologics Evaluation and Research, biological Response Modifiers Advisory Committee Meeting #33 (2002)
  36. US FDA Center for Biologics Evaluation and Research, Guidance for industry (1998): Guidance for Human Somatic Cell Therapy and Gene Therapy.
  37. Vile, R.G., Russell, S.J., and Lemoine, N.R. (2000): Cancer gene therapy: hard lessons and new courses. Gene Therapy, 7, 2-8
  38. Vogt, P., Reed, S. In: Vogt, P., Reed, S. eds. (1998): Cyclin Dependent Kinase (CDK) Inhibitors, Berlin, Heidelberg: Springer-Verlag, 139-148
  39. Winn, R.A., Bremnes, R.M., Bemis, L., Franklin, W.A., Miller, Y.E., Cool, C. and Heasley, L.E. (2002): Gamma-catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene, 21, 7497-7506
  40. Wu, Q., Moyana, T. and Xiang, J. (2001): Cancer gene therapy by adenovirus-mediated gene transfer. Curr. Gene Ther., 1, 101-122
  41. Zhang, L.Y., Ying, W.T., Mao, Y.S., He, H.Z., Liu, Y.L., Wang, H.X., Liu, F., Wang, K., Zhang, D.C., Wang, Y, Wu, M., Qian, X.H. and Zhao, X.H. (2003): Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches. World J. Gastroenterol., 9, 650-654
  42. Verdier, F. and Descotes, J. (1999): Preclinical safety evaluation of human gene therapy products. Toxicological Sciences, 47, 9-15